Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 17/20 | 0.62 |
| ▸ | CHUK | O15111 | 5/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589932 | 0.86 | IKBKB (0.71) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL14031320 | 0.86 | IKBKB (0.64) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL5034416 | 0.85 | IKBKB (0.63) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4590164 | 0.85 | IKBKB (0.59) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4590095 | 0.83 | IKBKB (0.65) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL5037997 | 0.82 | IKBKB (0.65) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4590171 | 0.82 | IKBKB (0.60) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4590333 | 0.81 | IKBKB (0.62) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4590118 | 0.81 | IKBKB (0.62) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL4590457 | 0.81 | IKBKB (0.69) | IKBKBCHUKAURKAFLT3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269291-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2008-10-30 | — | — | US | claimed |
| US-20080269291-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2008-10-30 | — | — | US | disclosed |
| US-20080269291-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2008-10-30 | — | — | US | disclosed |
| US-20080269291-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2008-10-30 | — | — | US | disclosed |
| EP-1948187-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007062318-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269291-A1 | Chemical Compounds | IDO2, IKBKG, NFKBIA | IKBKB 8/4885CHUK 28/4885AURKA 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.